Syros Pharmaceuticals, Inc. (SYRS) DCF Valuation

Syros Pharmaceuticals, Inc. (SYRS) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

Syros Pharmaceuticals, Inc. (SYRS) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Evaluate Syros Pharmaceuticals, Inc. (SYRS) financial prospects like an expert! This (SYRS) DCF Calculator comes with pre-filled financial data and offers total flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 2.0 15.1 23.5 14.9 9.9 12.1 14.7 17.8 21.6 26.2
Revenue Growth, % 0 661.5 55.62 -36.65 -33.23 21.44 21.44 21.44 21.44 21.44
EBITDA -72.7 -79.2 -79.6 -87.6 -157.2 -12.1 -14.7 -17.8 -21.6 -26.2
EBITDA, % -3668.82 -524.82 -339.04 -588.39 -1582.08 -100 -100 -100 -100 -100
Depreciation 2.7 3.0 3.0 3.0 2.3 4.2 5.1 6.2 7.6 9.2
Depreciation, % 137.34 20.11 12.85 19.94 22.67 35.11 35.11 35.11 35.11 35.11
EBIT -75.4 -82.2 -82.7 -90.5 -159.4 -12.1 -14.7 -17.8 -21.6 -26.2
EBIT, % -3806.16 -544.93 -351.89 -608.33 -1604.74 -100 -100 -100 -100 -100
Total Cash 91.4 174.0 130.4 202.3 139.5 12.1 14.7 17.8 21.6 26.2
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 20.2 2.3 3.0 1.7 .0
Account Receivables, % 1017.05 15.44 12.68 11.38 0
Inventories .3 .0 .0 .0 .0 .4 .4 .5 .6 .8
Inventories, % 14.63 0.000006625588 0 0.00000672043 0 2.93 2.93 2.93 2.93 2.93
Accounts Payable 5.9 3.6 3.7 6.4 11.5 6.8 8.3 10.1 12.2 14.8
Accounts Payable, % 295.31 23.87 15.72 43.08 116.18 56.54 56.54 56.54 56.54 56.54
Capital Expenditure -12.6 -3.3 -1.2 -1.2 -.3 -3.3 -4.1 -4.9 -6.0 -7.3
Capital Expenditure, % -637.64 -22.1 -5.3 -8.34 -2.74 -27.7 -27.7 -27.7 -27.7 -27.7
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -75.4 -84.0 -86.4 -47.1 -159.4 -10.9 -13.2 -16.1 -19.5 -23.7
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -99.9 -68.4 -85.2 -41.4 -150.6 -18.5 -11.5 -14.0 -17.0 -20.6
WACC, % 8.58 8.58 8.58 4.97 8.58 7.86 7.86 7.86 7.86 7.86
PV UFCF
SUM PV UFCF -64.8
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -21
Terminal Value -358
Present Terminal Value -246
Enterprise Value -310
Net Debt -77
Equity Value -233
Diluted Shares Outstanding, MM 28
Equity Value Per Share -8.22

What You Will Get

  • Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
  • Real-World Data: Syros Pharmaceuticals’ financial data pre-filled to kickstart your analysis.
  • Automatic DCF Outputs: The template automatically computes Net Present Value (NPV) and intrinsic value for you.
  • Customizable and Professional: A refined Excel model that adjusts to your valuation requirements.
  • Built for Analysts and Investors: Perfect for evaluating projections, assessing strategies, and enhancing efficiency.

Key Features

  • Customizable Research Parameters: Adjust essential inputs such as drug development timelines, market penetration rates, and R&D expenditures.
  • Instant Valuation Metrics: Automatically computes intrinsic value, risk-adjusted NPV, and other key financial indicators.
  • High-Precision Analytics: Leverages Syros Pharmaceuticals’ actual financial data for accurate valuation results.
  • Streamlined Scenario Testing: Easily evaluate various hypotheses and analyze the resulting impacts.
  • Efficiency-Boosting Tool: Avoid the complexity of creating detailed financial models from the ground up.

How It Works

  • Download: Obtain the comprehensive Excel file featuring Syros Pharmaceuticals, Inc. (SYRS) financial data.
  • Customize: Modify projections, including anticipated revenue growth, EBITDA %, and WACC.
  • Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
  • Test Scenarios: Develop various projections and instantly analyze different outcomes.
  • Make Decisions: Leverage the valuation results to inform your investment approach.

Why Choose This Calculator for Syros Pharmaceuticals, Inc. (SYRS)?

  • User-Friendly Interface: Tailored for both novices and seasoned analysts.
  • Customizable Inputs: Easily adjust parameters to suit your financial assessments.
  • Real-Time Feedback: Observe immediate changes to Syros' valuation as you modify inputs.
  • Preloaded Financials: Comes equipped with Syros' current financial data for swift evaluations.
  • Relied Upon by Experts: Utilized by investors and financial analysts for informed decision-making.

Who Should Use This Product?

  • Investors: Evaluate Syros Pharmaceuticals' valuation before making stock transactions.
  • CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts.
  • Startup Founders: Understand how biotech companies like Syros Pharmaceuticals are appraised.
  • Consultants: Provide expert valuation reports tailored for clients in the pharmaceutical sector.
  • Students and Educators: Utilize real-time data to learn and instruct on valuation strategies.

What the Template Contains

  • Preloaded SYRS Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.